A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy

Publication date

2019-06-14

Authors

Cadrin-Tourigny, Julia
Bosman, Laurens P.ORCID 0000-0002-7847-4607
Nozza, Anna
Wang, Weijia
Tadros, Rafik
Bhonsale, Aditya
Bourfiss, Mimount
Fortier, Annik
Lie, Øyvind H.
Saguner, Ardan M.

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by_nc

Abstract

Aims Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC) is characterized by ventricular arrhythmias (VAs) and sudden cardiac death (SCD). We aimed to develop a model for individualized prediction of incident VA/ SCD in ARVC patients. Methods Five hundred and twenty-eight patients with a definite diagnosis and no history of sustained VAs/SCD at baseline, and results aged 38.2 ± 15.5 years, 44.7% male, were enrolled from five registries in North America and Europe. Over 4.83 (interquartile range 2.44–9.33) years of follow-up, 146 (27.7%) experienced sustained VA, defined as SCD, aborted SCD, sustained ventricular tachycardia, or appropriate implantable cardioverter-defibrillator (ICD) therapy. A prediction model estimating annual VA risk was developed using Cox regression with internal validation. Eight potential predictors were pre-specified: age, sex, cardiac syncope in the prior 6 months, non-sustained ventricular tachycardia, number of premature ventricular complexes in 24 h, number of leads with T-wave inversion, and right and left ventricular ejection fractions (LVEFs). All except LVEF were retained in the final model. The model accurately distinguished patients with and without events, with an optimism-corrected C-index of 0.77 [95% confidence interval (CI) 0.73–0.81] and minimal over-optimism [calibration slope of 0.93 (95% CI 0.92–0.95)]. By decision curve analysis, the clinical benefit of the model was superior to a current consensus-based ICD placement algorithm with a 20.6% reduction of ICD placements with the same proportion of protected patients (P < 0.001). Conclusion Using the largest cohort of patients with ARVC and no prior VA, a prediction model using readily available clinical parameters was devised to estimate VA risk and guide decisions regarding primary prevention ICDs (www.arvcrisk.com).

Keywords

Arrhythmogenic right ventricular cardiomyopathy, Implantable cardioverter-defibrillators, Sudden cardiac death, Ventricular arrhythmias, Cardiology and Cardiovascular Medicine, Journal Article

Citation

Cadrin-Tourigny, J, Bosman, L P, Nozza, A, Wang, W, Tadros, R, Bhonsale, A, Bourfiss, M, Fortier, A, Lie, Ø H, Saguner, A M, Svensson, A, Andorin, A, Tichnell, C, Murray, B, Zeppenfeld, K, Van Den Berg, M P, Asselbergs, F W, Wilde, A A M, Krahn, A D, Talajic, M, Rivard, L, Chelko, S, Zimmerman, S L, Kamel, I R, Crosson, J E, Judge, D P, Yap, S C, Van Der Heijden, J F, Tandri, H, Jongbloed, J D H, Guertin, M C, Van Tintelen, J P, Platonov, P G, Duru, F, Haugaa, K H, Khairy, P, Hauer, R N W, Calkins, H, Te Riele, A S J M & James, C A 2019, 'A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy', European Heart Journal, vol. 40, no. 23, pp. 1850-1858. https://doi.org/10.1093/eurheartj/ehz103